Athenaeum Scientific Publishers – published Melissa Rubio’s article on Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy
Current pharmacologic management of Chronic Obstructive Pulmonary Disease (COPD) is aimed at improving symptoms and preventing exacerbations, yet none can alter the natural progression of lung function decline typical of the disease. Autologous-derived PRP-PC may prevent lung function decline and improve quality of life.
281 patients with COPD underwent autologous cellular therapy with PRP-PC. Baseline lung function and quality of life data were collected and re-assessed after 3 months and after at least 12 months and compared to baseline.
Participants undergoing autologous cellular therapy with PRP-PC had a clinically significant increase in lung function after 3 months with an average improvement in FEV1 % predicted of 7.2% from baseline. Those measured after at least one year had an average improvement in FEV1% predicted of 6.88% from baseline. There was also a significant improvement in subjective quality of life from baseline in both groups. Compared with findings in the literature that FEV1 typically declines over time, participants in this study had a significant increase in lung function on average.
Innovative treatments such as autologous cellular therapy can be a safe, effective option for preventing lung function decline over time. These therapies should be an option for patients where pharmacologic management has failed, or as an adjunct treatment.